# A SU2C Catalyst® Trial of a PD1 Inhibitor With or Without a Vitamin D Analog for the Maintenance of Pancreatic Cancer

> **NCT03331562** · PHASE2 · COMPLETED · sponsor: **Translational Genomics Research Institute** · enrollment: 24 (actual)

## Conditions studied

- Pancreatic Cancer
- Pancreas Adenocarcinoma
- Advanced Pancreatic Cancer
- Metastatic Pancreatic Cancer
- Metastatic Pancreatic Adenocarcinoma

## Interventions

- **DRUG:** Pembrolizumab
- **DRUG:** paricalcitol
- **DRUG:** placebo

## Key facts

- **NCT ID:** NCT03331562
- **Lead sponsor:** Translational Genomics Research Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-12-27
- **Primary completion:** 2020-06-29
- **Final completion:** 2020-07-10
- **Target enrollment:** 24 (ACTUAL)
- **Last updated:** 2022-12-27

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03331562

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03331562, "A SU2C Catalyst® Trial of a PD1 Inhibitor With or Without a Vitamin D Analog for the Maintenance of Pancreatic Cancer". Retrieved via AI Analytics 2026-07-17 from https://api.ai-analytics.org/clinical/NCT03331562. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*